지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.6
- 수록면
- 32 - 40 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: We evaluated oral metronomic capecitabine (MC) compared to intravenous doxorubicin in patients with advanced or metastatic hepatocellular carcinoma (HCC).
Methods: From January 2013 to December 2015, patients with Child-Pugh class A or early B were randomized either to MC group (500 mg twice daily continuously) or doxorubicin group (60 mg∕m2 every 21 days).
Results: Forty patients were included in each group. The baseline clinical characteristics of the enrolled patients were well balanced between the two groups. No complete response (CR) was reported in either group. In MC group, 2 patients (5%) had partial response (PR), 25 patients (62.5%) stable disease (SD) and 27 patients (67.5%) had disease control. In doxorubicin group, 4 patients (10%) achieved PR, 24 patients (60%) SD and 28 patients (70%) had disease control. The 6 months overall survival (OS) was 77.5% for MC and 75% for doxorubicin. The one year OS was 47.5% for MC and 42.5% for doxorubicin (P=0.521). The median OS survival was 10.2 months for MC and 9.6 months for doxorubicin (95% confidence interval, 3.2–6.5). The 6 month progression-free survival (PFS) was 45% for MC and 50% for doxorubicin. The one year PFS was 12.5% for MC and 7.5% for doxorubicin (P=0.289). The median time to progression was 3.4 months for MC and 3.1 months for doxorubicin. On multivariate analysis no significant impact for tumor stage, previous transhepatic arterial chemoembolization, portal vein thrombosis or median baseline alpha fetoprotein on OS.
Conclusion: MC showed response rate and survival outcome comparable to doxorubicin in advanced HCC but with a more favorable toxicity profile.
Methods: From January 2013 to December 2015, patients with Child-Pugh class A or early B were randomized either to MC group (500 mg twice daily continuously) or doxorubicin group (60 mg∕m2 every 21 days).
Results: Forty patients were included in each group. The baseline clinical characteristics of the enrolled patients were well balanced between the two groups. No complete response (CR) was reported in either group. In MC group, 2 patients (5%) had partial response (PR), 25 patients (62.5%) stable disease (SD) and 27 patients (67.5%) had disease control. In doxorubicin group, 4 patients (10%) achieved PR, 24 patients (60%) SD and 28 patients (70%) had disease control. The 6 months overall survival (OS) was 77.5% for MC and 75% for doxorubicin. The one year OS was 47.5% for MC and 42.5% for doxorubicin (P=0.521). The median OS survival was 10.2 months for MC and 9.6 months for doxorubicin (95% confidence interval, 3.2–6.5). The 6 month progression-free survival (PFS) was 45% for MC and 50% for doxorubicin. The one year PFS was 12.5% for MC and 7.5% for doxorubicin (P=0.289). The median time to progression was 3.4 months for MC and 3.1 months for doxorubicin. On multivariate analysis no significant impact for tumor stage, previous transhepatic arterial chemoembolization, portal vein thrombosis or median baseline alpha fetoprotein on OS.
Conclusion: MC showed response rate and survival outcome comparable to doxorubicin in advanced HCC but with a more favorable toxicity profile.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Loss of endogenous estrogen increases cardiac toxicity by doxorubicin
Journal of Biomedical and Translational Research
2017 .12
-
Anti-inflammatory activity of doxorubicin on lipopolysaccharide-induced hyperactivation of spleen cells
예방수의학회지
2018 .06
-
Reversal of Doxorubicin-induced Cardiotoxicity by Using Phytotherapy: A Review
Journal of Pharmacopuncture
2017 .01
-
Anti-tumoric effects of pH-sensitive nanoparticle loaded doxorubicin and celecoxib on NSCLC cells
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Effects of medical communication curriculum on perceptions of Korean medical school students
Korean Journal of Medical Education
2018 .01
-
유방암 환자의 cyclophosphamide, doxorubicin 유발 부작용에 대한 약침을 포함한 통합 암 치료 1례
대한암한의학회지
2018 .01
-
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
Cancer Research and Treatment
2020 .01
-
Verification of the Correlation between Progression-free Survival and Overall Survival Considering Magnitudes of Survival Post-progression in the Treatment of Four Types of Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
Cancer Research and Treatment
2016 .01
-
A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
Cancer Research and Treatment
2019 .01
-
Prognostic Value in Preoperative Veterans RAND-12 Mental Component Score on Clinical Outcomes for Patients Undergoing Minimally Invasive Lateral Lumbar Interbody Fusion
Neurospine
2024 .03
-
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Cancer Research and Treatment
2016 .01
-
Protective effects and mechanism of coenzyme Q10 and vitamin C on doxorubicin-induced gastric mucosal injury and effects of intestinal flora
The Korean Journal of Physiology & Pharmacology
2021 .01
-
Surface characteristics and bioactivity of minocycline-treated Ti-6Al-4V alloy
Oral Biology Research
2018 .01
-
Polymer-surfactant nanoparticles for improving oral bioavailability of doxorubicin
Journal of Pharmaceutical Investigation
2017 .01
-
A formulated red ginseng extract inhibits autophagic flux and sensitizes to doxorubicin-induced cell death
Journal of Ginseng Research
2019 .01
-
Phase II Study of Compliance and Morbidity with 4 Cycles of Taxotere Followed by 4 of Doxorubicin-Cyclophosphamide for Adjuvant Treatment of Operable Breast Cancer Patients
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Cancer Research and Treatment
2022 .04
-
Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
Cancer Research and Treatment
2021 .01
-
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran
Asian Pacific journal of cancer prevention : APJCP
2015 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
당신은 누구인가 외 4편
이근화
계간 서정시학
2017
.02
The efficacy of laparoscopic cholecystectomy without discontinuation in patients on antithrombotic therapy
Jong Hyuk Yun
,
Hae Il Jung
,
Hyoung Uk Lee
외 2명
Annals of Surgical Treatment and Research
2017
.03
Byron’s Reworking of Ossian’s Fingal in The Death of Calmar and Orla
Yu
,
Jie-Ae
신영어영문학
2017
.02
“Distant Music” and Failed Words : Joyce’s Narrative Style in “The Dead”
Kim
,
Jungmin
신영어영문학
2017
.02
Emerging Roles of Lymphatic Vasculature in Immunity
Ki-Wook Kim
,
Joo-Hye Song
Immune Network
2017
.02
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2017-514-001558478